Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Kymera Therapeutics Inc

Healthcare US KYMR

74.61USD
1.40(1.91%)

Last update at 2026-06-04T20:00:00Z

Day Range

72.6675.29
LowHigh

52 Week Range

9.6045.31
LowHigh

Fundamentals

  • Previous Close 73.21
  • Market Cap2057.34M
  • Volume752686
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-170.46301M
  • Revenue TTM79.41M
  • Revenue Per Share TTM1.29
  • Gross Profit TTM -117.42200M
  • Diluted EPS TTM-2.47

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -154.80800M -100.21700M -45.59300M -41.24600M -21.46700M
Minority interest - - - - -
Net income -151.83100M -97.99500M -43.94500M -41.29200M -21.46700M
Selling general administrative 43.83M 36.34M 18.23M 7.98M 3.77M
Selling and marketing expenses - - - - -
Gross profit 46.83M 72.83M 34.03M 2.93M -
Reconciled depreciation 2.98M 2.40M 1.76M 0.82M 0.20M
Ebit -161.25600M -100.53000M -46.30400M -42.20500M -21.45100M
Ebitda -154.63200M -100.04200M -45.47800M -40.37500M -21.24600M
Depreciation and amortization 6.62M 0.49M 0.83M 1.83M 0.20M
Non operating income net other 6.45M 0.31M 0.71M - -
Operating income -161.25600M -100.53000M -46.30400M -42.20500M -21.45100M
Other operating expenses 208.08M 173.36M 80.34M 45.14M 21.45M
Interest expense 0.18M 0.17M 0.12M 0.05M 0.02M
Tax provision - - - - -
Interest income 6.62M 0.49M 0.83M 1.00M 0.00000M
Net interest income 6.45M 0.31M 0.71M 0.96M -0.01600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.97700M -2.22200M -1.64800M 0.05M -
Total revenue 46.83M 72.83M 34.03M 2.93M 0.00000M
Total operating expenses 208.08M 173.36M 80.34M 45.14M 21.45M
Cost of revenue - - - - -
Total other income expense net 6.45M 0.31M 0.71M 0.96M -0.01600M
Discontinued operations - - - - -
Net income from continuing ops -154.80800M -100.21700M -45.59300M -41.24600M -21.46700M
Net income applicable to common shares -154.80800M -100.21700M -54.64300M -41.24600M -21.46700M
Preferred stock and other adjustments - - 9.05M - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 575.76M 603.13M 605.90M 487.18M 116.70M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 11.67M 9.71M 8.86M 5.56M 0.89M
Total liab 180.79M 112.98M 146.27M 203.29M 191.11M
Total stockholder equity 394.97M 490.15M 459.64M 283.89M -74.40600M
Deferred long term liab - - - - -
Other current liab 34.39M -8.27800M -7.60400M -67.40200M 4.57M
Common stock 0.00600M 0.00600M 0.00500M 0.00400M -
Capital stock 0.00600M 0.00600M 0.00500M 0.00400M 0.00000M
Retained earnings -530.75200M -383.79000M -228.98200M -128.76500M -76.45600M
Other liab - 28.25M 39.36M 77.94M 29.64M
Good will - - - - -
Other assets - 9.15M 8.14M 1.62M 1.77M
Cash 109.97M 68.39M 47.98M 31.00M 76.02M
Cash and equivalents - - - - -
Total current liabilities 85.69M 63.26M 101.03M 110.62M 34.57M
Current deferred revenue 37.88M 63.26M 101.03M 170.39M 23.35M
Net debt -25.29200M -51.06000M -30.01300M -13.01100M -54.82200M
Short term debt 6.34M 3.94M 3.60M 3.26M 3.38M
Short long term debt - - - - -
Short long term debt total 84.67M 17.34M 17.96M 17.99M 21.19M
Other stockholder equity 926.27M 878.88M 689.27M -74.39800M 2.04M
Property plant equipment - 13.33M 11.88M 20.69M 22.08M
Total current assets 405.32M 559.49M 567.61M 302.34M 92.84M
Long term investments 61.43M 152.33M 125.19M 162.53M -
Net tangible assets - 490.15M 459.64M 283.89M -74.40600M
Short term investments 264.92M 338.77M 394.44M 265.20M 15.94M
Net receivables 18.76M 2.54M 0.14M 1.43M 0.29M
Long term debt - - - - -
Inventory 0.00000M -12.25000M -8.99000M -163.38700M -
Accounts payable 7.08M 4.33M 4.00M 4.37M 3.28M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.55200M -4.94900M -0.66000M -0.12800M 0.00600M
Additional paid in capital - - - - -
Common stock total equity - 0.00600M 0.00500M 0.00400M -
Preferred stock total equity - - - - -
Retained earnings total equity - -383.79000M -228.98200M -128.76500M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 7.93M -122.02200M -98.76800M 11.46M 1.77M
Deferred long term asset charges - - - - -
Non current assets total 170.44M 43.64M 38.30M 184.84M 23.86M
Capital lease obligations 84.67M 17.34M 17.96M 17.99M 21.19M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 20.52M -98.23800M -422.58800M -15.95400M -15.95400M
Change to liabilities 5.03M 12.74M 118.39M 53.90M 0.82M
Total cashflows from investing activities 20.52M -99.83500M -422.58800M -16.48600M -1.35600M
Net borrowings -1.13000M -0.84900M -0.55400M -0.37100M -0.29500M
Total cash from financing activities 153.00M 250.28M 289.26M 34.91M 52.93M
Change to operating activities 2.30M 6.08M 7.91M 2.79M 1.63M
Net income -154.80800M -100.21700M -45.59300M -41.24600M -21.46700M
Change in cash 20.43M 21.50M -45.19600M 36.33M 33.71M
Begin period cash flow 54.09M 32.59M 77.79M 41.46M 7.75M
End period cash flow 74.53M 54.09M 32.59M 77.79M 41.46M
Total cash from operating activities -153.08500M -128.94600M 88.13M 17.91M -17.86300M
Issuance of capital stock 149.82M 243.11M 289.65M 35.21M 53.23M
Depreciation 2.98M 2.40M 1.76M 0.82M 0.20M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - 8.71M 6.88M - -
Change to account receivables -2.40100M 0.58M -0.57700M -1.43300M -0.14800M
Sale purchase of stock 4.30M 8.02M 276.29M - -
Other cashflows from financing activities 4.30M 8.02M 93.14M 35.28M 53.23M
Change to netincome 35.48M 24.99M 7.09M 1.64M 1.09M
Capital expenditures 2.84M 1.60M 9.10M 0.53M 1.36M
Change receivables - 0.58M -0.57700M - -
Cash flows other operating -41.76300M -69.43200M 120.40M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 20.43M 21.50M -45.19600M - -
Change in working capital -37.62300M -61.92300M 124.87M 56.69M 2.31M
Stock based compensation 35.48M 24.97M 5.19M 1.20M 0.65M
Other non cash items 0.89M 5.83M 0.33M 0.44M 0.44M
Free cash flow -155.92100M -130.54300M 79.03M 17.37M -19.21900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
KYMR
Kymera Therapeutics Inc		 1.40 1.91% 74.61 - - 27.67 5.50 23.97 -13.1574
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Inc

200 Arsenal Yards Boulevard, Watertown, MA, United States, 02472

Key Executives

Name Title Year Born
Dr. Bruce L. Booth D.Phil., DPHIL, Ph.D. Co-Founder & Chairman 1974
Dr. Nello Mainolfi M.D., Ph.D. Co-Founder, Pres, CEO & Director 1979
Mr. Bruce N. Jacobs CFA Chief Financial Officer NA
Dr. Jared A. Gollob M.D. Chief Medical Officer 1965
Ms. Elaine Caughey Chief Bus. Officer NA
Kevin Dushney Sr. VP of IT & Operations NA
Mr. Michael J. Todisco VP of Accounting & Fin. 1965
Mr. Vijay Sabesan Sr. VP of Technical Operations 1972
Ms. Melissa Brody VP of Bus. Devel. NA
Ms. Karen Weisbach VP of People & Culture NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions